

Environmental, Social and Governance Report

環境、社會及管治報告

For The Nine Months Ended
31 December 2022
截至2022年12月31日止九個月

2022



天大藥業有限公司
TIANDA PHARMACEUTICALS LIMITED

股份代號 Stock Code: 00455 (於開曼群島註冊成立之公司)
(Incorporated in the Cayman Islands with limited liability)

CONTENTS

目錄

2	About This Report	關於本報告
2	Basis of Preparation	編製依據
2	Materiality	重要性
2	Quantification	量化
2	Consistency	一致性
2	Balance	平衡
3	ESG Strategies	環境、社會及管治策略
3	Value, Mission and Vision	價值觀、使命及願景
3	Report Assurance	可靠性保證
3	Access to the Report	發佈渠道
3	Stakeholders Engagement	持份者參與
5	Identification of Material Issues	重大事宜識別
5	Board Statement	董事會聲明
5	Approval	批准
6	The Material ESG Issues	重大環境、社會及管治事宜
7	Social	社會
7	Community Contribution	社區貢獻
9	Health and Safety	健康與安全
11	Development and Training	發展及培訓
12	Employment	僱傭
14	Labour Standards	勞工準則
15	Supply Chain Management	供應鏈管理
16	Product Responsibility	產品責任
18	Anti-corruption	反貪污
19	Environmental	環境
19	Emissions	排放物
25	Use of Resources	資源使用
28	The Environment and Natural Resources	環境及天然資源
28	Climate Change	氣候變化
30	Awards And Recognitions	獎項與嘉許
30	Stakeholders' Feedback	持份者的意見回饋

ABOUT THIS REPORT

Tianda Pharmaceuticals Limited (the Company) and its subsidiaries (collectively the Group) is hereby pleased to issue this Environmental, Social and Governance Report (the/this ESG Report). The purpose is to publicly report to shareholders, employees, customers, partners and stakeholders regarding the practice, performance and development of the Group in fulfilling environmental policies and corporate social responsibility during the Reporting Period.

Basis of Preparation

This ESG Report is prepared in accordance with Appendix 27 to the Rules Governing the Listing of Securities (the Listing Rules) on The Stock Exchange of Hong Kong Limited (the Stock Exchange) – “Environmental, Social and Governance Reporting Guide” (the ESG Guide). This Report covers the period from 1 April 2022 to 31 December 2022 (the Reporting Period), whereas certain content would be in a retrospective or prospective basis (as appropriate). The Group adheres to the principles of materiality, quantification, balance and consistency to report on its Environmental, Social and Governance (ESG) measures and performances.

Materiality

The Group communicated with relevant stakeholders to identify extent of impact of ESG-related issues on stakeholders, and ESG issues with high materiality have been responded and disclosed in this Report.

Quantification

The key performance indicators disclosed in this report are supported by quantitative data and measurable standards. The sources of all applicable data, calculation tools, methodologies, references and conversion factors applied are disclosed when presenting emissions data.

The data and information used in this report are referenced from the Group’s official documents, statistical data and management and operation information of and collected by the Group in accordance with relevant internal policies. Financial data is extracted from or calculated based on the Group’s audited annual financial statements for the nine months ended 31 December 2022. The Group has established internal controls and a formal review process to ensure that any information presented in this ESG Report is as accurate and reliable as possible.

Balance

The Company provides an unbiased ESG performance of each year avoiding selections, omissions or presentation that may inappropriately influence a decision or judgement to the public.

Consistency

To facilitate the comparison of ESG performance of each year, the Group uses the same reporting and calculation methods when reasonably possible, and records any significant changes in relevant sections in detail.

Information regarding corporate governance has been addressed in the annual report for the period from 1 April 2022 to 31 December 2022 in pursuance of Appendix 14 of the Listing Rules.

關於本報告

天大藥業有限公司（本公司）及其附屬公司（合稱本集團）欣然發佈本環境、社會及管治報告。旨在向股東、員工、客戶、合作夥伴及持份者公開報告本集團在本報告期間履行環境政策及企業社會責任方面的實踐、績效與發展情況。

編製依據

本環境、社會及管治報告乃根據香港聯合交易所有限公司（聯交所）證券上市規則（上市規則）附錄27《環境、社會及管治報告指引》而編製。該報告涵蓋2022年4月1日至2022年12月31日期間（本報告期間），部分內容適當向前追溯或向後延伸。本集團遵守重要性、量化、平衡及一致性準則申報其環境、社會及管治措施及表現。

重要性

本集團通過與各有關持份者溝通，確認 ESG 相關事宜對各利益相關方的影響程度，並對重要性程度較高的議題進行重點回應和披露。

量化

本報告中披露的關鍵績效指標由定量數據及可衡量標準支持。所有適用數據來源、計算工具、方法、參考文獻及轉換系數在呈列排放數據時均已披露。

本報告所用數據及資料引述自本集團官方文件、統計數據、本集團根據有關內部政策收集的管理及營運資料。財務數據乃引自或根據本集團截至2022年12月31日止九個月的經審核年度財務報表計算得出。本集團已制訂內部監控及正式審核程序，以確保於本環境、社會及管治報告呈列的任何資料均盡可能準確可靠。

平衡

本公司提供不偏倚各年度之環境、社會及管治表現，避免選擇、遺漏或陳述可能不適當地影響公眾決策或判斷。

一致性

為了方便比較各年度之環境、社會及管治表現，本集團在合理可能情況下採用相同的報告及計算方法並詳細記錄相關章節的重大變動。

有關企業管治的資料已根據上市規則附錄十四於2022年4月1日至2022年12月31日止期間之年報中載述。

ESG Strategies

In line with the ESG Guide, the Board of Directors of the Company (the Board) has overall responsibility for the Group's ESG strategy and reporting. The Board evaluates and determines the ESG-related risks of the Group, and ensures an appropriate ESG risk management and internal control systems are in place that can effectively identify risks. The Board believes that sound ESG performance is critically important to the sustainable development of the Group's business and the community. The Board is committed not only to achieving a healthy financial position, but also to promoting environmental protection, social responsibility and effective corporate governance.

Value, Mission and Vision

The Group adheres to the philosophy of "Tianda for health!" as core value, which shows the company's continuous commitment to the passion and pursuit of health and care. The Group fully realizes our social responsibilities and insists on the corporate mission - to adopt market-driven and innovative approach; follow international standards and assure quality & safety control; strengthen good management practice; value talents; enhance research and development; offer quality products. Focus on cost efficiency and create better returns for shareholders; improve service to make our business partners more satisfied; boost up the incentive mechanism to make our employees more devoted to work. Our vision is committed to becoming a leading pharmaceutical enterprise that sets its footholds in China while seeking to expand its presence worldwide.

Report Assurance

The Board understands its responsibility of ensuring the authenticity and effectiveness of the information in the Report. The Board has reviewed the Report and confirmed that there are no false representations or misleading statements contained in this Report.

Access to the Report

This Report can be read and downloaded from the HKEX News websites of the Hong Kong Exchanges and Clearing Limited (www.hkexnews.hk), and the official website of the Company (<https://www.tiandapharma.com>).

Stakeholders Engagement

Stakeholders' participations are critical factors for establishing the Group's ESG strategies. The Group has communicated with relevant stakeholders to understand and prioritize their concerns and expectations. The Group has evaluated, and responded to their feedbacks in order to improve the Group's ESG performance.

With the support from business partners, customers and other stakeholders, the Group will lead the industry to a future where development is more sustainable. Ultimate goal is to achieve a win-win situation and create value to the Group, various stakeholders and the community.

環境、社會及管治策略

跟《環境、社會及管治報告指引》的要求一致，本公司董事會（董事會）對本集團環境、社會及管治策略及匯報承擔全部責任。董事會評估及釐定本集團有關環境、社會及管治方面的風險，並確保設有合適的環境、社會及管治風險管理及內部監控系統，能有效辨識風險。董事會相信，良好的環境、社會及管治表現對本集團業務及社區的可持續發展至關重要。董事會不僅致力於實現穩健財務狀況，亦致力於推廣環境保護、社會責任及高效的企業管治。

價值觀、使命及願景

本集團秉承「您的健康是天大的事！」的核心價值觀，表達了天大藥業源源不斷奉獻健康與關愛的願望與追求。本集團時刻牢記企業所應承擔的各項社會責任，並堅持企業使命 - 以市場為導向，以創新為推力；遵循國際標準，嚴控質量安全；加強規範管理，高度重視人才；提高研發水平，提供優質產品。注重效益，為投資者創造更好回報；提升服務，使合作夥伴更滿意；完善激勵機制，令員工更愉快投入工作。我們的願景為致力成為立足中國，輻射全球的領先醫藥企業。

可靠性保證

董事會對本報告所載信息的真實性及有效性負責。董事會已審閱本報告並確認其內容不存在任何虛假記載和誤導性描述。

發佈渠道

本報告可通過香港交易及結算所有有限公司披露易網站(www.hkexnews.hk)及本公司網站(<https://www.tiandapharma.com>)瀏覽和下載。

持份者參與

持份者的參與是制定環境、社會及管治策略的關鍵要素。本集團與各有關持份者溝通，從而理解及優先考慮他們的關注與期望。本集團亦已分析及回應他們的反饋，從而提升本集團環境、社會及管治的表現。

在業務夥伴、客戶及其他持份者的支持下，本集團將帶領行業邁向更符合可持續發展的未來。最終目標達致雙贏，為本集團、各持份者以及社區創造價值。

Stakeholders
持份者

Communication channels
溝通渠道

Concerns and expectation
關注與期望

Shareholders and Investors
股東及投資者

General meeting
股東大會
Announcements
公告
Company's website
公司網頁
Press releases
媒體發報

Return on investments
投資回報
Transparent disclosures
公開透明的披露

Government / Regulatory Authorities
政府/監管機構

Regular conversation with regulatory authorities
定期與監管機構對話
Inspection and supervision
檢查督查
Communication with local departments
與當地部門交流

Compliance with laws and regulations
遵守法律及法規
Proper tax payment
按時足額納稅
Production safety
安全生產
Cultivation of local economic development
促進地方經濟發展

Customers
顧客

Website, brochures, annual reports and other published information
網站、宣傳冊、年報及已發佈的其他資料
Email and customer service hotline
電郵及客戶服務熱線
Feedback forms
意見反饋表

Safe and high quality products and services
安全和優質的產品及服務
Consumer right protection
保護消費者權益
Protect customer privacy
保護客戶私隱
Fair and reasonable pricing
公平和合理定價

Suppliers
供應商

Business meetings, supplier conferences, phone calls, interviews
業務會議、供應商會議、電話、面談
Review and assessment
審核及評估
Tendering process
投標流程

Long-term business relationship
長期營銷關係
Fair and reasonable pricing
公平和合理定價

Employees
員工

Employee trainings
員工培訓
Internal publication and intranet of the Company
公司內刊和內聯網
Performance assessments and evaluations
績效評估及考核
Regular staff individual interview
定期員工單獨約談

Protect the rights of employees
保障員工權益
Career development and training opportunities
職業發展和培訓機會
Create a good working environment
營造良好的工作環境

Community
社區

Company's website
公司網頁
Social media platforms
社交媒體平臺
Charity and social investment
慈善及社區投資

Community participations
社區參與

Identification of Material Issues

The Group's ESG working team identifies relevant ESG issues and assesses their materiality to the Group's business as well as the Group's stakeholders by the way of materiality assessment. The materiality assessment has based on the continuous discussions and communications with the stakeholders. Through various abovementioned channels, the Group understands expectations from major stakeholders.

After our assessments of (1) feedbacks from stakeholders; (2) the core business model and operation procedures of the Group; and (3) the statutory requirements for information disclosure, the Group has identified 17 key issues on sustainable development related to its operation (the Material ESG Issues).

Disclosures relating to the Material ESG Issues identified have been included and focused on this ESG Report pursuant to the requirements of the ESG Guide.

Board Statement

As the highest decision-making body for ESG affairs, the Board holds the overall accountability for the company's ESG governance, including developing the sustainability strategies and reporting, evaluating and determining the Group's ESG-related risks and ensuring that appropriate and effective ESG risk management and internal control systems are in place.

During the Reporting Period, the Group understands the relevant stakeholders' views towards the sustainable development of the Group, and also identify material issues that facilitate us to understand and evaluate the Group's ESG performance and formulate relevant strategies. Moreover, the Group has established an ESG working team, which consists of management and employees from each functional department. The team is responsible for planning of the Group's sustainable development, monitoring the implementation of the relevant policies and writing the ESG Report. The Board reviews, analyzes and evaluates the Group's ESG report annually, and will take appropriate measures and make recommendations in a timely manner regarding the key risks and policies implementation. The implementation of such measures is carried out by management and all relevant departments under the supervision of the Board.

In the future, through continuous improvement on internal corporate governance structure; develop clearer ESG objectives and targets; enhancement on internal control systems and risk management and urged all responsible departments to take the initiative in achieving environmental goals and dealing with climate change, the Group will further raise the standard and efficiency of its ESG governance. The Group will also dedicate more resources to reducing the impacts on environment caused by the operation to grasp the opportunities brought by sustainable development..

Approval

After management review, this ESG Report was approved by the Board on 28 April 2023.

重大事宜識別

本集團的環境、社會及管治工作小組，通過重要性評估的方式，識別出相關的環境、社會及管治事宜，並評估其對本集團業務以及本集團持份者的重要性。重要性評估乃基於與持份者的持續討論及溝通。本集團透過上述多種途徑了解主要持份者不同期望。

經過我們評估(1)持份者的反饋；(2)本集團自身的核心業務模式和運營流程；以及(3)法定信息披露的要求後，本集團識別出17項與其運營相關的可持續發展關鍵事宜（重大環境、社會及管治事宜）。

有關已發現的重大環境、社會及管治事宜的披露已根據《環境、社會及管治報告指引》載入本環境、社會及管治報告作重點匯報。

董事會聲明

作為環境、社會及管治事務的最高決策機構，董事會肩負本公司ESG治理的整體責任，包括制定可持續發展戰略以及報告、評估和確定本集團與環境、社會及管治相關的風險，並確保建立適當和有效的環境、社會及管治風險管理和內部監控系統。

本報告期內，本集團了解相關持份者對本集團可持續發展的看法，並識別出有助於我們了解及評估本集團的環境、社會及管治表現的重要事項，從而製訂相關策略。此外，本集團已成立環境、社會及管治工作小組，由各個職能部門的管理人員及僱員組成。小組負責本集團可持續發展的規劃、監督相關政策的實施，以及撰寫環境、社會及管治報告。董事會每年對本集團的環境、社會及管治報告進行審閱、分析及評估，並就當中主要風險及政策執行情況適時採取適當措施及作出建議。在董事會的監督下，這些措施的實施由管理層及所有相關部門貫徹執行。

未來，通過不斷完善企業內部管治結構、制定更清晰的環境、社會及管治目標及指標、加強內部監控系統和風險管理，並敦促所有專責部門在實現環境目標和應對氣候變化方面採取主動，本集團將提升在環境、社會及管治方面的管治水平及效率；並會持續投放更多資源，減少營運對環境所造成的影響，從而抓緊可持續發展帶來的機遇。

批准

本環境、社會及管治報告經管理層確認後，於2023年4月28日獲董事會通過。

THE MATERIAL ESG ISSUES

The table below shows the Material ESG Issues which were determined to be material to the Group, together with the two subject areas (Subject Areas) and various aspects of each Subject Area (Aspects) on the ESG Guide to which they relate, based on the assessment performed by the ESG working team. This ESG Report mainly covers the policies, measures and performance of the Group's business in relation to these issues, for the Reporting Period:

ESG Subject Areas and Aspects as set forth in the ESG Guide		The Material ESG Issues of the Group	《環境、社會及管治報告指引》所載的環境、社會及管治的主要範疇及層面	本集團的重大環境、社會及管治事宜
1. Social			1. 社會	
1.1	Community Contribution	Community programs and donation	1.1 社區貢獻	社區計劃及捐款
1.2	Health and Safety	Workplace health and safety	1.2 健康與安全	工作環境健康與安全
1.3	Development and Training	Employee development and training	1.3 發展及培訓	僱員發展及培訓
1.4	Employment	Labour practices	1.4 僱傭	勞工常規
1.5	Labour Standards	Anti-child and forced labour	1.5 勞工準則	禁止童工及強制性勞動
1.6	Supply Chain Management	Supply chain management	1.6 供應鏈管理	供應鏈管理
1.7	Product Responsibility	Product health and safety and labelling	1.7 產品責任	產品健康與安全以及標籤
1.8	Anti-corruption	Anti-corruption and money laundering	1.8 反貪污	反貪污及洗黑錢
2. Environmental			2. 環境	
2.1	Emissions	Greenhouse gas and exhaust gas emissions management Wastewater treatment Solid waste treatment General waste management	2.1 排放物	溫室氣體及廢氣排放管理 廢水處理 固體廢棄物處理 一般廢棄物管理
2.2	Use of Resources	Use of energy Use of water Use of packaging materials	2.2 資源使用	能源使用 用水 包裝物料使用
2.3	The Environment and Natural Resources	Air quality	2.3 環境及天然資源	空氣質素
2.4	Climate Change	Significant climate-related issues	2.4 氣候變化	重大氣候相關事宜

重大環境、社會及管治事宜

下表列示根據環境、社會及管治工作小組進行的評估，被認為對本集團而言屬重大的環境、社會及管治事宜，以及有關事宜所涉及的环境、社會及管治報告指引的兩個主要範疇(主要範疇)及每個主要範疇的多個層面(層面)。本環境、社會及管治報告涵蓋本報告期間本集團業務的政策、措施及表現：

1. SOCIAL

Community

1.1 Community Contribution *Community programs and donation*

Adhering to the mission of “Care for a Better World”, the Group and Mr. Fang Wen Quan, the Company’s Chairman and Managing Director, have been deeply devoting to the community over the years to show their greater commitments to community services, including but not limited to donations to support the poverties, education and talent development, healthcare, scientific research, environmental protection, culture and arts, etc.

The Group actively performs its corporate social responsibilities and joins hands with different social institutions for public welfare establishments. At the same time, it encourages employees to reward the community and society by participating in various public welfare activities. During the Reporting Period, the Group and its employees participated in the following community charity campaign and activities:

- In Hong Kong, participated in the “Dress Casual Day” organized by the Community Chest and encouraged employees to participate in donations and charity activities in the community;
- In Kunming, the labour union of Meng Sheng Pharmaceutical actively participated in the “Delivery of Warmth” activities, showing consolation and care to the model workers and employees in difficulties during various festivals;
- The Group supported the college-enterprise talent cooperation program, participating in campus recruitment organized by different colleges and universities, including Zhuhai College of Science and Technology, Guangxi University of Chinese Medicine, Guangdong Ocean University, Guilin Life and Health Career Technical College, Guangxi Agricultural Vocational College, Hubei College of Chinese Medicine, Guangdong Food and Drug Vocational College, and provided more than 60 internship positions for students;

1. 社會

社區

1.1 社區貢獻 *社區計劃及捐款*

秉承「關心社會，共同發展」的使命，本集團及本公司董事長兼董事總經理方文權先生多年來致力回饋社會、熱誠資助社會公益，包括但不限於捐資扶貧、教育和人才發展、醫療衛生、科學研究、環境保護、文化藝術等。

本集團積極踐行企業社會責任，與不同社會機構共同經營公益事業，同時鼓勵員工走進社會，深入社區，參與各類公益活動，以實際行動回饋社會。於本報告期間，本集團及其員工參與了以下社區公益及活動：

- 在香港，參與由香港公益金主辦的「便服日」，鼓勵員工參與捐款及社區慈善工作；
- 在昆明，盟生藥業工會積極參與「送溫暖」慰問活動，在不同節日中向區內勞動模範和困難職工送上關愛；
- 本集團支援校企人才合作計畫，參加珠海科技學院、廣西中醫藥大學、廣東海洋大學、桂林生命與健康職業技術學院、廣西農業職業技術學院、湖北中醫藥高等專科學校、廣東食品藥品職業技術學校等院校舉辦的校園招聘，並先後為院校學生提供了逾60多個實習崗位；

Fighting the virus together

The COVID-19 pandemic continued to ravage the world. Adhering to the mission of “Tianda for Health!”, the Group actively joins the world in the fight against the pandemic by leveraging the unique strengths of traditional Chinese medicine.

- In Hong Kong, the Group launched the public welfare campaign “Together we fight the virus with free consultations and medicines” and partnered with Po Leung Kuk to provide complimentary online TCM consultations and anti-epidemic health webinars. It also donated anti-epidemic health care kits to Hong Kong citizens and charity groups in need, benefiting more than two thousand people;
- In Beijing, the Group donated anti-epidemic drugs and supplies, such as ventilators, to Tsinghua University and its affiliated hospitals to support the national anti-epidemic and treatment efforts;
- In addition to donating anti-epidemic supplies, the Company accelerated its production capacity and made every effort to manufacture urgently needed drugs to ensure market supply. At the same time, it urgently deployed anti-epidemic drugs through its TCM clinic chain, TDMall, to support the fight against the epidemic in Zhuhai and the whole country;
- The Group kept providing free online consultation services through the “Cloud-based Global Anti-epidemic Chinese Medicine Platform” launched in the “TDMall on Cloud”, which offered anti-epidemic health consultations for people across the country, and allowed appointment-making for emergency drug purchases;
- On the other hand, the Group adopted different preventive measures to ensure the safety and health of its employees, including introducing work from home policy, maintaining strict cleaning and disinfection management, arranging internal education to raise awareness of epidemic prevention, and encouraging employees to get vaccinated.

疫境同行

新冠肺炎疫情持續肆虐，本集團秉承「您的健康是天大的事」這一使命，發揮中醫藥優勢，積極支援全球抗疫。

- 在香港，本集團發起「贈醫施藥同心抗疫」公益大行動，並與保良局合作，提供網上免費中醫義診和防疫健康講座，並捐贈防疫保健包予有需要的香港市民和慈善團體，受惠人數逾兩千人；
- 在北京，本集團向清華大學及其附屬醫院捐贈防疫藥品及呼吸機等抗疫設備，支援國內疫情防控及救治工作；
- 除捐贈抗疫物資外，本公司提速產能，全力生產市場急需藥品，努力保障市場供應。同時，透過旗下中醫館連鎖「天大館」，緊急調配抗疫藥物支援珠海及全國抗疫；
- 本集團透過開設於「雲上天大館」的「全球中醫雲端科技抗疫平台」，多次開展網上義診服務，為全國人民提供防疫健康諮詢，並進行應急藥品購買的預約；
- 另外，本集團採取不同防疫措施以確保員工的安全和健康，當中包括：准許辦公室人員在家辦公、實施嚴格清潔消毒管理、安排內部教育提高防疫意識，以及鼓勵員工接種疫苗等。

Promoting the development of Chinese Medicine

The Group values the development and inheritance of TCM, striving to promote the culture of TCM.

- The Group organized TCM health seminars and forums in collaboration with schools, charities, and commercial organizations in Hong Kong, mainland China and Australia in order to promote the healthcare knowledge of TCM;
- The Group reached out to many communities in the Greater Bay Area, including supporting the program “Promoting Chinese Medicine Culture and Contributing to the Development of a Healthy Zhuhai” in Zhuhai and co-organizing the “Promotion of Chinese Medicine Culture” event to provide free Chinese medical services and health education, treat people who felt unwell and promote correct health concepts;
- The Group actively organized various parent-child activities about TCM, providing opportunities for parents and children to learn and come into contact with TCM in order to cultivate their interests and inherit the TCM culture.

Employment and Labour Practices

1.2 Health and Safety

Workplace health and safety

In addition to complying with the labour laws and regulations as mentioned in section 1.4, the Group also strictly abides by its relevant local laws and regulations in relation to workplace health and safety, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Occupational Safety and health ordinance of Hong Kong
- Law of the PRC on the Prevention and Control of Occupational Diseases;
- Production Safety Law of the PRC; and
- Regulation on Work-Related Injury Insurances of the PRC.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the laws and regulations in relation to workplace health and safety as mentioned above.

推動中醫藥發展

本集團重視中醫藥發展及傳承，致力弘揚中醫藥文化。

- 在香港、中國內地和澳大利亞，本集團聯合學校、慈善團體及商業機構舉辦中醫健康講座、論壇，普及中醫保健知識；
- 本集團深入粵港澳大灣區多個社區，包括在珠海響應「傳播中醫藥文化，助力健康珠海建設」計劃，協辦中醫藥文化宣傳服務活動，提供中醫義診服務及健康教育分享，為市民治療身體不適，傳播正確的健康理念；
- 本集團積極舉辦各種中醫親子活動，為家長和孩子提供了認識及接觸中醫藥的機會，培養孩子對中醫藥的興趣，推動中醫藥文化傳承。

僱傭及勞工常規

1.2 健康與安全

工作環境健康與安全

除遵守1.4章節勞工法律及規例外，本集團亦嚴格遵守其當地之有關工作環境健康及安全的法律及規例，當中對本集團有重大影響的相關法律及規例主要包括下列所述：

- 《香港職業安全及健康條例》；
- 《中華人民共和國職業病防治法》；
- 《中華人民共和國安全生產法》；及
- 《中華人民共和國工傷保險條例》。

於本報告期間，據我們所知及所據有的信息，本集團並未發現及察覺到任何違反上述有關工作環境健康及安全的法例及規例之情形。

The Group has established a set of policies which is focused on maintaining a healthy and safe working environment, and which includes the following requirements:

- The facilities operated by employees should meet health and safety standards;
- Expert advices should be obtained to identify health and safety risks in the operations and the corresponding mitigating actions that should be taken;
- Relevant information and training should be provided to employees in respect of risks to their health and safety which may arise in their work;
- Conduct annual health checkups for employees each year and arrange special occupational health checks for relevant personnel; and
- The Group provides medical insurance coverage to its staff. Employees also can enjoy concessionary consultation and treatments in the Group's TCM clinics.

The Group has established a mechanism for monitoring occupational health and safety, as well as procedures for dealing with related risks. Employees are invited to participate in the determination of occupational health and safety precautionary measures. Accident reporting and investigation procedures have also been adopted for the follow-up of any health and safety incidents.

In the view of COVID-19 pandemic, the Group pays extra attention in creating a safe and healthy environment for its employees. Alcoholic sanitizers were placed in the office area, and buildings are sterilized in a frequent interval to prevent germs dispersion.

The Group has strictly complied with the relevant laws and regulations on providing safe work environment and protecting its employees from any occupation hazard. Going on, the Group will continue to strive for a safe and healthy work environment for our employees and workers.

There is no work-related fatalities nor lost days due to work injury occurred in the Reporting Period.

本集團已訂立一套專注於維持健康與安全工作環境的政策，當中包括下列規定：

- 操作的設施應符合健康及安全標準；
- 應取得專家的意見以識別營運中的健康及安全風險，並應採取相應的降低風險措施；
- 就僱員工作中可能產生的健康及安全風險應向其提供有關資料及培訓；
- 安排員工進行一年一次的健康體檢，並為相關崗位人員安排了特定職業健康檢查；及
- 本集團為員工提供醫療保險保障。員工亦可於集團旗下的中醫診所享用諮詢及診療優惠。

本集團已建立監察職業健康及安全的機制，以及處理有關風險的程序，邀請僱員參與職業健康及安全預防措施的釐定。就跟進任何健康及安全事故，本集團亦採取事故報告及調查程序。

鑒於COVID-19疫情，本集團特別注意為其僱員打造安全健康的環境。在辦公室區域放置酒精洗手液，及大廈樓宇頻繁消毒，以防細菌傳播。

本集團於提供安全工作環境及保障僱員避免職業性危害方面嚴格遵守相關法律及法規。今後，本集團將持續致力為僱員及工人提供安全及健康的工作環境。

本報告期間沒有因工作關係死亡及因工傷損失工作日。

The occupational safety and health related policies and practices are regularly reviewed by the Group so that preventive and corrective measures are implemented to minimize occupational health and safety hazards. During the Reporting Period, the Group complied with laws and regulations in relation to health and safety and our management provided confirmation on the compliance.

1.3 Development and Training ***Employee development and training***

The Group strives to promote the long-term development of its employees by providing learning opportunities that broaden their skills and make them to be valuable assets to the Group.

Various employee training programs and seminars held by internal/external organisations are offered to employees, including in the areas of finance, governance, rules and regulations, supervisory and managerial skills, as well as various technical training courses relating to their respective job duties.

During the Reporting Period, we conducted several production safety educations, fire prevention trainings and emergency fire drills to enhance the employees' familiarity with the safety knowledge, which significantly improved the awareness of all employees about occupational safety, strengthened the protection to employees and reduced the chances of accidents. The Group also conducts safety education and training for each on-board new employee, whereby only those who passed the relevant examination will be employed.

The Group also actively organized outdoor development training in order to enhance employees' awareness of social environmental protection.

本集團定期審閱職業安全及健康相關政策及常規，實施預防及糾正措施以減少職業安全及健康的隱憂。於本報告期間，本集團遵守有關健康及安全的法律及規例，而我們的管理層已確認合規情況。

1.3 發展及培訓 ***僱員發展及培訓***

本集團致力於向其員工提供拓展技能的學習機會，藉以推動員工的長期發展，使彼等成為本集團的寶貴資產。

本集團向員工提供各種由內/外部團體舉辦的員工培訓項目及研討會，包括金融、管治、規則及規例、監督及管理技能，以及與彼等各自的工作職責有關的各種技術培訓課程等領域。

本報告期間，我們內部多次開展生產安全教育、防火培訓，以及消防應急演練，加強員工對安全知識的熟知，從而顯著提高了全體員工對職業安全的認知，加強員工保障，以及減低意外事故機會。本集團亦對每一位入職的新員工進行安全教育培訓，有關考試合格的員工方能上崗。

本集團亦積極組織員工參加戶外拓展培訓，增強員工對社會環境保護的意識。

During the Reporting Period, staff training across the Group amounted to a total of 4,207 hours and the breakdown is as follows:

於本報告期間，本集團員工培訓總時數達4,207小時，分佈概況如下：

Employee	僱員	Period from 1 April 2022 to 31 December 2022 2022年4月1日至2022年12月31日期間		Year ended 31 March 2022 2022年3月31止年度	
		Proportion of Training Hours 培訓小時佔比數 %	Average Training Per Employee 每名員工平均培訓 in hour 按時數	Proportion of Training Hours 培訓小時佔比數 %	Average Training Per Employee 每名員工平均培訓 in hour 按時數
Female	女性	50.39	7.41	51.88	6.84
Male	男性	49.61	8.09	48.12	3.29
By grade	按職級				
Senior management	高級管理人員	2.97	6.58	2.22	4.04
Middle management	中級管理人員	13.12	8.00	14.16	15.90
Other staff	其他員工	83.91	6.98	83.62	6.33

1.4 Employment Labour practices

The Group has always adhered to its mission of "Nurture Talents and Strengthen the Team" in human resources management. With this mission and as an equal opportunity employer, the Group is committed to provide a working environment without discrimination and inequality, where safety and health of employees are being protected. Opportunities for continuous development and training will be provided to employees as well.

The Group has production bases and/or offices in China, Hong Kong and Australia with employees hired. The Group strictly abides by relevant local laws and regulations in relation to labour, where the relevant laws and regulations that have significant impact on the Group mainly include the following:

- Labor Law of the PRC ;
- Labor Contract Law of the RPC ;
- Employment Ordinance of Hong Kong; and
- National Employment Standards of Australia.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the abovementioned laws and regulations in relation to employment.

1.4 僱傭 勞工常規

本集團於人力資源管理，一直遵循「知人善用、強化團隊」的使命。藉著此使命及作為平等機會僱主，本集團致力提供一個沒有歧視及不平等的工作環境，使員工安全及健康會受到保障，亦會為員工提供持續發展及培訓的機會。

本集團在中國、香港及澳大利亞設有生產基地及/或辦事處，並聘有員工。本集團嚴格遵守當地勞工法律及規例，當中對本集團有重大影響的相關法律法規主要包括下列所述：

- 《中華人民共和國勞動法》；
- 《中華人民共和國勞動合同法》；
- 《香港僱傭條例》；及
- 《澳大利亞國家就業標準》。

於本報告期間，據我們所知及據有的信息，本集團並未發現及察覺到任何違反上述有關勞工的法律法規之情形。

To ensure the employees follow professional and ethical practices, the Group has developed clear work processes with robust control mechanisms which have been clearly communicated to all employees. Certain policies governing employees' affairs, such as payroll, attendance, termination, are clearly set out in staff employment contracts or appointment letters and complied strictly.

The Group also aims to promote the diversity of workforce, including in terms of age, gender and nationality, as well as a culture of equal opportunity.

Employee Benefits

The Group cares about the physical and mental health development of the employees and is committed to taking care of every employee. The Group regularly organizes various after-work activities in order to promote networking among colleagues and increase the employees' sense of belonging to the Group.

The management regularly reviews the Group's remuneration policy in relation to relevant market standards.

During the Reporting Period, the breakdown of employees and turnover rate by gender, age group, employment type and region is set out below:

為確保員工能遵從專業及道德常規，本集團已制訂具備穩健監控機制的明確工作流程，並已清晰地傳達給全體員工。若干規管僱員事務的政策，如薪資、出席及終止聘用，已清楚載於勞動合同或僱員委任函件中，並嚴格遵守。

本集團亦旨在提升員工多樣性，包括年齡、性別及國籍，以及平等機會文化。

員工福利

本集團關心員工的精神健康和身心發展，致力照顧每位員工的福祉。本集團定期舉辦不同工餘活動，促進同事之間的聯誼交流，並藉此增加員工對本集團的歸屬感。

本集團的管理層就有關市場標準定期檢討本集團的薪酬政策。

於本報告期間，按性別、年齡組別、僱傭類型及地區劃分的僱員及僱員流失比率分佈概況載列如下：

Number of employees by gender, age group, employment type and region

按性別、年齡組別、僱傭類型及地區劃分的人數

Number of employees	僱員人數	As at 31 December 2022 於2022年12月31日	As at 31 March 2022 於2022年3月31日
By gender	按性別		
Female	女性	354	330
Male	男性	368	345
By age group	按年齡組別		
Aged below 30	30歲以下	176	148
Aged 31 – 40	31至40歲	254	254
Aged 41 – 50	41至50歲	211	207
Aged 51 or above	51歲或以上	81	66
By employment type	按僱傭類型		
Full time	全職	714	663
Part time	兼職	8	12
By region	按地區		
Hong Kong	香港	29	37
China	中國	691	635
Australia	澳大利亞	2	3

Employee turnover rate by gender, age group and region
按性別、年齡組別及地區劃分的僱員流失比率

Employee turnover rate	僱員流失比率	Period from 1 April 2022 to 31 December 2022 2022年4月1日至2022年12月31日期間	Year ended 31 March 2022 2022年3月31日止年度
Overall	整體	22.51%	40.08%
By gender	按性別		
Female	女性	22.46%	28.71%
Male	男性	22.56%	50.96%
By age group	按年齡組別		
Aged below 30	30歲以下	30.26%	72.56%
Aged 31 – 40	31至40歲	19.12%	36.89%
Aged 41 – 50	41至50歲	19.19%	30.67%
Aged 51 or above	51歲或以上	25.00%	9.78%
By region	按地區		
Hong Kong	香港	64.66%	63.59%
China	中國	20.70%	38.39%
Australia	澳大利亞	37.50%	90.00%

1.5 Labour Standards

Anti-child and forced labour

In addition to complying with the labour laws and regulations as mentioned in section 1.4, the Group also strictly abides by its relevant local laws and regulations in relation to child and forced labour, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Employment of Children Regulations of Hong Kong;
- Provisions on the Prohibition of Using Child Labor of the PRC; and
- Law of the PRC on the Protection of Minors.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the relevant laws and regulations in relation to child and forced labour as mentioned above.

The Group strictly prohibits the use of child and forced labour in the Group, and is committed to create a working environment that fully respects human rights.

1.5 勞工準則

禁止童工及強制性勞動

除遵守1.4章節勞工法律及規例外，本集團亦嚴格遵守其當地之有關童工或強制性勞動的法律及規例，當中對本集團有重大影響的相關法律法規主要包括下列所述：

- 《香港僱用兒童規例》；
- 《中華人民共和國禁止使用童工規定》；及
- 《中華人民共和國未成年人保護法》。

於本報告期間，據我們所知及據有的信息，本集團並未發現及察覺到任何違反上述有關童工或強制性勞動的法律法規之情形。

本集團嚴格禁止在本集團使用童工及強制性勞動，並致力於創建一個完全尊重人權的工作環境。

In addition to having well-established recruitment processes requiring background checks on candidates and reporting on exceptions found, the Group also performs regular reviews and inspections to detect the existence of any child or forced labour in the operations. Through the whistle-blowing mechanism, employees can voice out the injustice they face or report any suspicious matters. The management will investigate into any reported cases immediately, and take further follow-up actions if necessary.

Operating Practices

1.6 Supply Chain Management

The Group's medicine raw materials, medicine, Chinese herbal medicines and traditional Chinese medicine decoction pieces are mainly sourced from suppliers in mainland China while healthcare products are mainly from China and Australia. During the Reporting Period, the number of suppliers of the Group for the Reporting Period by geographical region is set out below:

	Number of suppliers
Mainland China	446
Australia	20
Hong Kong	9
Total	475

When the Group conducts pharmaceuticals products purchases, the selected item must be either manufactured by an enterprise who has passed the Good Manufacturing Practice (GMP) verification or wholesaled through a corporation with the Good Supply Practice (GSP) certificate.

When selecting suppliers, the Group considers factors such as the operation and production qualification, product quality, market prospect, service quality, environmental protection concept, business ethics and social responsibility, etc. The Group is inclined to select socially responsible suppliers and hopes to implement green supply chain practices in the Group's business. The Group is committed to creating a mutually beneficial and win-win partnership with the suppliers. Moreover, if any suppliers are found to be below our requirements and standards, the Group removes them from the approved supplier list to ensure that we produce the best quality of products using the high-quality raw materials.

除已建立應聘者背景審查的完善招聘流程及例外情況彙報程序外，本集團亦定期進行審查及檢查，以防止經營中存在的任何童工或強制性勞動。通過舉報機制，僱員能夠就其面對的不公正發聲或舉報任何可疑事項。管理層將立即調查任何舉報案例，並於必要時採取進一步後續行動。

營運慣例

1.6 供應鏈管理

本集團醫藥原材料及成藥、中藥材及中藥飲片主要由中國大陸供應商供應，而保健產品則主要來自中國及澳大利亞。於本報告期間，本集團的供應商數目按地區分佈如下：

	供應商數目
中國大陸	446
澳大利亞	20
香港	9
總數	475

本集團進行藥品採購時，所選品種必須是通過《生產質量管理規範》(GMP)認證的企業生產，或通過《經營質量管理規範》(GSP)認證的經營企業批發銷售。

本集團在選擇供應商時所考慮因素包括企業的運營及生產資質、產品品質、市場前景、供應商服務質素、環保理念、商業倫理及社會責任等。本集團傾向於選擇具有社會責任感的供應商，並希望將綠色環保踐行於本集團業務的供應鏈環節。本集團致力於打造與供應商互利共贏的合作關係。倘發現任何供應商未能符合我們的要求及標準，本集團從合格供應商清單中刪除該供應商，以確保我們使用高質量的原材料生產優質產品。

Not only do the Group focuses on the upstream suppliers, but the Group also emphasizes the development of long-term relationship with the downstream customers. On-time delivery is the fundamental key to manage the supply chain. To enhance the effectiveness and efficiency of delivering products to the customers, the Group has established an efficient supply chain management system that links between manufacturers, suppliers, distributors and retailers by optimising the allocation of resources. In this regard, the Group can provide best-quality products to our customers in a timely manner at the most reasonable price.

1.7 Product Responsibility

Product health and safety and labelling

The Group strictly abides by its relevant local laws and regulations in relation to product health and safety and labelling, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Medicinal Product Administration Law of the PRC;
- Regulations for the Implementation of the Drug Administration Law of the PRC;
- Measures for the Administration of Drug Registration;
- Good Manufacturing Practices for Pharmaceutical Products (National and local regions standards, if any);
- Good Supply Practice for Pharmaceutical Products (National and local regions standards, if any);
- Provisions on the Administration of Pharmaceutical Directions and Labels (National and local regions standards, if any);
- Pharmacopoeia of China;
- Notice of Strengthening the Supervision and Administration of TCM Decoction Pieces;
- National Pharmaceutical Packaging Standard; and
- Law of the PRC on Protection of Consumer Rights and Interests.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incident of non-compliance to the above laws and regulations in relation to product health and safety and labelling.

The medical products promoted and sold by the Group are all registered with the local authorities. Imported products are further supported by test and inspection report issued by the import ports or the place of origin.

本集團不僅關注上游供應商，亦重視與下游客戶發展長期關係。及時交貨是管理供應鏈的基礎環節。為提高向本集團客戶交付產品的有效性及效率，本集團已建立有效的供應鏈管理系統，通過優化資源配置來連接製造商、供應商、分銷商及零售商。因此，本集團能以最合理的價格及時向客戶提供最優質的產品。

1.7 產品責任

產品健康與安全以及標籤

本集團嚴格遵守其當地之有關產品健康與安全以及標籤的法律法規，當中對本集團有重大影響的相關法律法規主要包括下列所述：

- 《中華人民共和國藥品管理法》；
- 《中華人民共和國藥品管理法實施條例》；
- 《藥品註冊管理辦法》；
- 《藥品生產質量管理規範》（國家及當地地區標準，如有）；
- 《藥品經營質量管理規範》（國家及當地地區標準，如有）；
- 《藥品說明書和標籤管理規定》（國家及當地地區標準，如有）；
- 《中國藥典》；
- 《關於加強中藥飲片包裝監督管理的通知》；
- 《國家藥包材標準》；及
- 《中華人民共和國消費者權益保護法》。

於本報告期間，據我們所知及據有的信息，本集團並未發現及察覺到任何違反上述有關產品健康與安全以及標籤的法律及規例之情形。

本集團推廣及銷售的醫藥藥品均已向當地政府部門註冊；進口產品更需要獲得進口口岸的檢測報告或原產地的檢驗報告。

The medicines, healthcare products, Chinese medicinal materials and TCM decoction pieces sold by the Group must be verified by a third-party testing agency to ensure the content, heavy metals, pesticide residues, etc., are complied with standards.

The major subsidiaries of the Group engage in the manufacture and sales of pharmaceutical or TCM products have obtained the latest GMP and GSP certifications. As for product storage, the Group has reasonable storage arrangement according to the quality characteristics of the products, which is equipped with warehouse, air conditioning, and facilities for shading, ventilation, anti-moisture, pest control, rodent control and safety monitoring, etc.

Furthermore, the Group's warehouse is equipped with 24-hour automatic temperature and humidity monitoring system to maintain a good storage status of the products. Before delivery, the Group will check the products to ensure packaging integrity. We have dedicated departments responsible for product health and safety, as well as the compliance of labelling, and strictly adhere to product specifications and local government's regulations. During the Reporting Period, there was no recall of drugs due to health and safety issues.

Intellectual Property Rights

The Group attached great importance to intellectual property protection in order to better fulfil its product responsibility. The Group has registered wide range of trademarks and intellectual property rights for its products. No infringement is tolerated by the Group. Beyond that, dedicated department has been setup for intellectual property and trademarks management. The Group holds a strong belief that by respecting and protecting intellectual property, the Group can promote industry innovation and create a healthy and sustainable development of the industry.

Customers' Response

As the Group is committed to providing the highest standard of products, it values all feedbacks and complaints from the customers. The Group can be contacted through e-mail or customer hotline that is available in the package of the pharmaceutical products. Once complaints or feedbacks are received, the Group will examine the internal records and conduct relevant investigation in a prompt manner. Product recall will occur if they are below the internal and national quality standards. Moreover, the Group will perform the failure and root cause analyses. Prompt corrective and preventive actions will be taken accordingly to prevent similar incidents from recurring. During the Reporting Period, none of our products were recalled and the Group did not receive any complaints for the quality of the Group's products.

本集團所銷售的藥品、保健品、中藥材以及中藥飲片，均須要通過第三方檢測機構檢定，確定含量、重金屬、農藥殘留量等符合標準。

本集團從事藥品或中醫藥產品生產或銷售的主要附屬公司均已獲得最新版GMP及GSP認證。在產品儲存方面，本集團根據產品的質量特性對產品進行合理的儲存，配備相應的庫房及空調、同時配有避光、遮光、通風、防潮、防蟲、防鼠、安全監控等設施設備。

另倉庫配有24小時溫濕度自動監測系統，確保產品保持良好的儲存狀態。本集團在發貨前均要求進行出庫覆核，確保包裝完整性。我們設有專責部門，負責產品的健康與安全，以及標籤的合規事宜，一律嚴格遵守產品說明書及當地政府相關規定。本報告期間，本集團沒有涉及因健康與安全問題發生的藥品召回事件。

知識產權

本集團高度重視知識產權保護以更好地履行其產品責任。本集團已就其產品註冊多種類商標及知識產權。本集團絕不容忍任何侵權行為。此外，我們設有專責部門負責本公司知識產權及商標管理。本集團深信，通過尊重及保護知識產權，本集團能夠促進行業創新並推動行業健康及可持續發展。

客戶反應

本集團致力於提供最高標準的產品，因此其重視客戶的所有反饋及投訴。客戶可通過電子郵件或藥品包裝上的客戶熱線與本集團進行聯繫。一旦收到投訴或反饋，本集團將檢查內部記錄並迅速進行相關調查。如果產品低於內部及國家質量標準，將對產品進行召回。此外，本集團將查找分析問題根源，迅速採取相應的糾正和預防措施，以防止類似事件再次發生。本報告期內，並無發生產品召回或並無接獲本集團產品質量任何投訴的情況。

Customer privacy and data protection

The Group values and respects the customer privacy and data protection. As a clinical service provider, the Group handles a number of sensitive personal information of the patients. The privacy of customers and patients are vital to the Group. Aside from abiding the relevant laws and regulations, customer privacy protection allows the Group to gain customers' trust and maintain brand reputation. In view of this, the Group strives to protect the customers' and patients' privacy by developing internal guidelines. Staff are required to follow the listed procedure to handle the personal information of the customers and patients properly and prohibit any unauthorized access to the collected data.

Whistleblowing Policy

The Company is committed to achieving and maintaining a high standard of probity, openness, and accountability. A Whistleblowing Policy is in place to create a system for the employees and other stakeholders of the Company to raise concerns, in confidence, about possible improprieties. A designated email account and a dedicated hotline have been set up for this purpose. The identity of each whistleblower and all information provided in connection with a whistleblowing report will be treated with the strictest confidence.

1.8 Anti-corruption

Anti-corruption and money laundering

The Group strictly abides by its relevant local laws and regulations in relation to anti-corruption and money laundering, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Criminal Law of the PRC;
- Anti-corruption Law of the PRC;
- Prevention of Bribery Ordinance of Hong Kong; and
- Anti-money Laundering and Counter-Terrorism Financing Act 2006 of Australia.

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the above relevant laws and regulations in relation to anti-corruption and money laundering.

The Group has in place a number of policies addressing anti-corruption (such as acceptance of gifts and conflicts of interest), which provide guidance to employees in this area. The Group has also established policies and procedures to deal with money laundering in its operations.

客戶私隱及資料保護

本集團重視並尊重客戶私隱及資料保護，作為臨床服務提供者，本集團處理許多應診者的個人資料。客戶和應診者的隱私對本集團至關重要。除遵守相關法律法規外，客戶私隱保護亦使本集團獲得客戶的信任，並保持其品牌聲譽。有鑑於此，本集團通過制定內部守則以努力保障客戶和應診者的私隱。員工必須按照列出的程序妥善處理客戶和應診者的個人資料，並禁止未經授權的員工索取有關資料。

舉報政策

本公司致力達致和保持高標準的廉潔、開放和有責任性。本公司制定了舉報政策旨在設立一個保密系統為員工及其他持份者對懷疑不當的行為提出舉報。就此，指定舉報電子郵件賬戶和舉報專用熱線亦已設立。每位舉報人的身份與舉報報告內有關的一切資料將嚴格保密。

1.8 反貪污

反貪污及洗黑錢

本集團嚴格遵守其當地之有關反貪污及洗黑錢的法律法規，當中對本集團有重大影響的相關法律法規主要包括下列所述：

- 《中華人民共和國刑法》；
- 《中華人民共和國反腐敗法》；
- 《香港防止賄賂條例》；及
- 《澳大利亞2006年反洗黑錢和反恐主義融資法》。

於本報告期間，據我們所知及據有的信息，本集團並未發現及察覺到任何違反上述有關反貪污及洗黑錢的法律及規例之情形。

本集團現有多個解決反貪污的政策（如收受禮物及利益衝突），為僱員在這方面提供指引。本集團亦已制訂政策及程序以應對業務的洗黑錢活動。

In addition, the Group has established prevention system by setting up communication channels for faults and anti-corruption reporting. The whistle-blowing system can handle any breach of laws and regulations.

Trainings on anti-corruption and anti-money laundering are provided to employees in order to raise their awareness of the code of conduct as well as related procedures and guidelines.

During the Reporting Period, no legal case regarding corruption was brought against the Group or its employees.

2. ENVIRONMENTAL

The Group has established policies and management systems about environmental protection. All companies under the Group are required to strictly execute them in order to minimize the impacts from operations to the environment.

The Group also proactively encourages its staff to protect the environment through trainings, educations and communications. Ultimately, all employees will adopt eco-responsible habit no matter in workplace or daily lives.

The Group always keeps itself up-to-date on developments in local legislation and standards for environmental protection and is committed to achieving a level of environmental standards that goes beyond compliance.

2.1 Emissions

The Group strictly abides by its relevant laws and regulations in relation to pollutant emissions in the places of operation, where the relevant laws and regulations that have a significant impact on the Group mainly include the following:

- Environmental Protection Law of the People's Republic of China (the PRC);
- Atmospheric Pollution Prevention and Control Law of the PRC;
- Water Pollution Prevention and Control Law of the PRC; and
- Law of the PRC on the Prevention and Control of Environment Pollution by Solid Waste.

此外，本集團透過訂立申報及反貪污的溝通渠道，成立防範機制，舉報機制可應付任何違法及違規行為。

為提高各級僱員的行為守則以及有關程序及指引意識，本集團向僱員提供有關反貪污及反洗黑錢的培訓。

於本報告期間，並無對本集團或其僱員提出的貪污訴訟案件。

2. 環境

本集團已制訂環境保護政策及管理制，要求集團旗下各公司於營運中確切執行，力求將業務對環境的影響減至最低。

本集團亦透過培訓、教育及溝通積極鼓勵員工保護環境。最終讓所有員工無論在工作或日常生活中均能養成對生態環境負責任的習慣。

本集團時常保持自身緊跟當地環境保護立法及標準的最新發展，致力於實現高於合規程度的環境標準。

2.1 排放物

本集團嚴格遵守其營運地之有關污染廢物排放的法律法規，當中對本集團有重大影響的相關法律法規主要包括下列所述：

- 《中華人民共和國環境保護法》；
- 《中華人民共和國大氣污染防治法》；
- 《中華人民共和國水污染防治法》；及
- 《中華人民共和國固體廢物污染環境防治法》。

During the Reporting Period, to the best of our knowledge and information, the Group did not find and was not aware of any incidents of non-compliance to the above relevant laws and regulations in relation to pollutant emissions.

The principal business of the Group are “Chinese medicine business”, “Pharmaceuticals and medical technologies business” and “Medical and healthcare services” respectively. Among them, the “Chinese medicine business” mainly engages in trading of Chinese medicine products, while “Medical and healthcare services” are the operation of Chinese medical clinics and the provision of Chinese medicine services. These two businesses do not generate significant hazardous or non-hazardous emissions, wastes or pollutants.

The “Pharmaceuticals and medical technologies business” involves in pharmaceuticals research and development and manufacturing and production are performed by Tianda Pharmaceuticals (Zhuhai) Limited (Tianda Pharmaceuticals (Zhuhai)) and Yunnan Meng Sheng Pharmaceutical Co., Ltd. (Meng Sheng) (collectively the Two Manufacturing Subsidiaries).

The Group is very cautious in controlling the discharge of environmental pollutants in the production processes of pharmaceuticals. The exhaust gas, wastewater and solid waste (the Three Wastes) generated from the Group’s pharmaceutical production processes can all meet the requirements of the national emission standards, and the Three Wastes discharged are reduced to minimum level via efficient treatment systems and monitoring equipment.

Greenhouse gas and exhaust gas emissions management

The Group’s greenhouse gas (GHG) and exhaust gas emissions mainly come from carbon dioxide (CO₂) and exhaust gas generated during the production process respectively.

Our CO₂ emissions primarily come from the use of energy during pharmaceutical production (the CO₂ emissions data shown below is derived from the use of fuel in the production process – diesel and natural gas), followed by energy consumption in general daily business. The Group has developed various energy-saving initiatives to reduce the carbon footprint generated from energy consumption in general daily business (please refer to the section “2.2 Use of Resources – Use of energy” below).

於本報告期間，據我們所知及據有的信息，本集團並未發現及察覺到任何違反上述有關污染廢物排放的法律法規之情形。

本集團主要業務分別為「中醫藥業務」、「藥物和醫療科技業務」以及「醫療和保健服務」。當中，「中醫藥業務」主要從事中醫藥產品貿易銷售，而「醫療和保健服務」為經營中醫館，提供中醫診療服務，該兩項業務未有產生重大有害及無害排放、廢棄物或污染。

「藥物和醫療科技業務」涉及藥物研發及生產，並由天大藥業(珠海)有限公司(天大藥業(珠海))及雲南盟生藥業有限公司(盟生藥業)(統稱兩家生產附屬公司)負責生產。

本集團非常謹慎地把控藥品生產環節中環境污染物的排放，通過有效的處理系統及監控設備，本集團藥品生產環節中產生的廢氣、廢水及固體廢棄物(三廢)均能滿足國家的各項排放標準，並嚴格做到三廢最小化污染物排放量。

溫室氣體及廢氣排放管理

本集團溫室氣體及廢氣排放主要分別來自生產過程中產生的二氧化碳及廢氣。

我們二氧化碳排放主要源自藥品生產時能源使用(下文二氧化碳排放數據是源自生產過程中使用的燃料 – 柴油及天然氣)，其次是一般日常業務能源使用時所產生的二氧化碳。本集團已制訂多個節能措施，以幫助減少一般日常業務碳足跡(請參閱下文「2.2資源使用 – 能源使用」章節)。

The Group's pharmaceutical production business accounts for the largest proportion of the Group's overall CO₂ and exhaust gas emissions. In the production process, exhaust gas mainly comes from the boiler combustion, where deleterious substances mainly include sulfur dioxide (SO₂), nitric oxide (NO_x) and suspended particles (PM), as well as CO₂ generated from energy consumption during the production process (mainly including diesel and natural gas). In order to reduce the environmental and ecological adverse effects of GHG and exhaust gas emissions, the Group has established and implemented the following management policies:

- Increase the height of the flue in accordance with the authorities' regulations;
- Install PM dust arrester device;
- Clean chimney dust regularly to reduce dust emissions;
- Use relatively clean diesel with National VI Standard, and natural gas, as fuel for production to reduce the CO₂ generated from the using of diesel;
- Regularly remove boiler scale in the flue pipe to improve thermal efficiency and reduce diesel consumption; and
- Engage independent professional institutions to conduct air and exhaust gas testing annually to ensure the exhaust gas emission in compliance with the national emission standards.

During the Reporting Period, our SO₂ and NO_x emission indicators were far below the national emission standards as per our own and environmental protection departments' random checking.

The followings are the GHG and exhaust gas emissions data of the Two Manufacturing Subsidiaries during the Reporting Period. During the financial period for nine months ended 31 December 2022, the Two Manufacturing Subsidiaries contributed about 84% consolidated revenue of the Group.

本集團藥品生產業務佔集團整體二氧化碳及廢氣排放比例最大，生產過程中主要有鍋爐燃燒產生廢氣排放，當中的有害物質主要是二氧化硫、氮氧化物及懸浮粒子，以及生產時能源使用（主要包括柴油及天然氣）所產生的二氧化碳。為減少溫室氣體及廢氣排放對環境及生態帶來的不良影響，本集團設立和實施了以下各項管理政策：

- 按政府當局規定增加煙道高度；
- 安裝懸浮粒子捕塵裝置；
- 定期清潔煙囪灰塵，以減少煙塵排放量；
- 使用較為清潔的國VI標準的柴油及天然氣作為生產用燃料，以助減少使用柴油而產生的二氧化碳；
- 定期對鍋爐煙管進行除水垢處理，提高熱效能，減少柴油使用量；及
- 每年定期聘請獨立專業機構進行空氣及廢氣檢測，以確保廢氣排放符合國家排放標準。

於本報告期間，經我們自己和環保部門隨機檢測，我們二氧化硫及氮氧化物排放指標均遠低於國家排放標準。

以下為兩家生產附屬公司於本報告期間溫室氣體及廢氣排放數據。於截至2022年12月31日止九個月財政期間，兩間生產附屬公司貢獻集團綜合收入的84%。

Emissions	排放物	Unit	Emission Volume 排放量 Total 總計
Exhaust gas emissions	廢氣排放		
Sulfur dioxide (SO ₂)	二氧化硫	kg 千克	109
Nitric oxide (NO _x)	氮氧化物	kg 千克	438
Suspended particles (PM)	懸浮粒子	kg 千克	24
Greenhouse gas emissions	溫室氣體排放		
Scope 1 ¹ (Direct Emissions)	範圍1 ¹ (直接排放)	tCO ₂ e 噸二氧化碳當量	410
Scope 2 ² (Other Indirect Emissions)	範圍2 ² (其他間接排放)	tCO ₂ e 噸二氧化碳當量	2,675
Total Greenhouse Gas Emissions	溫室氣體排放總量	tCO ₂ e 噸二氧化碳當量	3,085
Intensity per HK\$'million revenue ³	每百萬港元收入密度 ³	tCO ₂ e 噸二氧化碳當量	7.52

¹ Scope 1 comprises of GHG emissions from stationary combustion sources and transportation. ¹ 範圍1包括固定燃燒源及運輸的溫室氣體排放。

² Scope 2 includes GHG emissions from electricity. ² 範圍2包括電力的溫室氣體排放。

³ Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period. ³ 密度的計算方式為本報告期間排放量除以本集團整體收入。

Wastewater treatment

The wastewater generated by the Group mainly includes production wastewater from the manufacturing process of pharmaceuticals and employees' domestic wastewater. Those wastewaters generated from pharmaceutical production process contain various chemicals, so they must not be directly discharged. The Group has taken measures to ensure these wastewaters are properly treated and complies with the regulatory standard requirements. Wastewaters are then discharged via designated municipal waste sewage pipes.

The Group's two pharmaceutical production bases in Zhuhai and Kunming have installed wastewater treatment systems. The production wastewater and domestic wastewater generated in the production bases are processed by our sewage treatment systems to reach the standards (i.e. the "Integrated Wastewater Discharge Standard" and the "Wastewater Quality Standards for Discharge to Municipal Sewers") and pass the acceptance test before discharged into the municipal sewage pipe network. Finally, the wastewater is further processed in the municipal centralized sewage treatment systems. Our sewage treatment stations adopt advanced biological treatment processes, which mainly include Anaerobic/Anoxic/Oxic (A/A/O) process and Bioactive Carbon process. Wastewater are filtered by sedimentation, and undergone anoxic and anaerobic biochemical treatment, etc., to effectively reduce the pollutants contained in the wastewater (for examples, SS, COD, BOD₅, ammonia nitrogen, total phosphorus, etc.) before the decomposition process, where the emission standards are complied with the national regulations.

廢水處理

本集團產生的廢水主要包括在藥品生產製造過程中的生產廢水和員工的生活廢水。藥品製造過程產生的廢水含有各種化學物質，因此不可直接排放，本集團已採取措施確保這些廢水經過妥善處理，以符合法定標準要求，廢水再透過市政指定廢水管道排出。

本集團在珠海市及昆明市的兩家製藥基地均設有污水處理系統。生產廢水和生活廢水經基地污水處理系統達標（即《污水綜合排放標準》以及《污水排入城鎮下水道水質標準》）、及檢驗合格後，排入市政污水管網，最後再經由市政污水處理系統集中處理。我們的污水處理站採用先進生物處理工藝，污水處理工藝主要是厭氧/缺氧/好氧工藝及生物活性碳工藝，廢水經過沉澱過濾、缺氧及厭氧菌生物處理等，有效降低廢水中的污染物含量後（例如水中的懸浮物含量、化學需氧量、生物需氧量、氨氮、總磷等）進行分解處理，達到國家法規排放標準。

The Group commissions qualified third-party institutions to conduct regular inspection annually, and during the Reporting Period, the sewage discharge indicators were in accordance with national emission standards.

The followings are the wastewater emission data of the Two Manufacturing Subsidiaries during the Reporting Period:

Wastewater	廢水	Unit 單位	Emission Volume 排放量 Total 總計
Wastewater	廢水	metric ton 公噸	20,822
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	50.782

¹ Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

¹ 密度的計算方式為本報告期間排放物量除以本集團整體收入。

Solid waste treatment

The Group's solid wastes generated from the pharmaceutical production process primarily include two types, namely non-hazardous solid wastes and hazardous solid wastes.

The Group has taken a number of practical and effective measures to reduce the environmental burden of solid wastes and to maximise the utilisation of resources, such as:

- The approach for solid wastes treatment is to have centralized collection at first, and then sort by categories, and allocate appropriate storage space for temporary storage of the categorized wastes;
- Non-hazardous solid wastes are centrally stored in the designated locations, and are processed periodically and timely by the local sanitation department or outsourced services providers;
- When the weekly processing volume of the non-hazardous solid waste exceeds the normal level, the dedicated department will investigate the reasons behind, and make recommendations and/or follow-up actions for control purpose;
- In compliance with the national standards for storage and treatment of hazardous solid wastes, the hazardous solid wastes are properly packed and stored in designated storage areas, and are processed by qualified contractors in due course;
- Recycles and reuses glass, cardboard, paper materials, metal, printing cartridges and batteries. Sets up collection facilities placed across factories; and

本集團每年定期委託具有資質的第三方進行檢測，而本報告期內污水排放指標均符合國家排放標準。

以下為兩家生產附屬公司於本報告期間廢水排放數據：

固體廢棄物處理

本集團藥品生產製造過程所產生的固體廢棄物主要為兩類，無害固體廢棄物及有害固體廢棄物。

本集團為減少固體廢棄物帶來的環境負擔及實現資源的最大化利用採取了許多實際有效的措施，如：

- 固體廢棄物的處理方法為先集中收集，後分類處理，並配置合適的分類貯存場所暫存廢棄物；
- 無害固體廢棄物指定位置集中存放，經由當地環衛局或外判服務商定期及時清理處理；
- 當無害固體廢棄物每週處理量超出常規水平，專責部門會查找原因，並提交處理意見及或後續行動以進行控制；
- 按照國家危險廢棄物的存儲標準，有害廢棄物均妥善封裝存放於指定貯存區，適時由合資格承辦商定時專項處理；
- 回收玻璃、紙板、紙質材料、金屬、打印墨盒及電池再利用，並在工廠各處設置回收設施；及

- Sell the waste plastic, metallic and paper packaging materials to recyclers for comprehensive utilization.

The followings are the solid waste data generated by the Two Manufacturing Subsidiaries during the Reporting Period:

Solid waste	固體廢棄物	Unit 單位	Emission Volume 排放量 Total 總計
Non-hazardous waste	無害廢棄物	metric ton 公噸	15
Intensity per HK\$ million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	0.037
Hazardous waste	有害廢棄物	metric ton 公噸	2
Intensity per HK\$ million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	0.005

¹ Intensity is calculated by dividing the emission volume by the Group's total revenue during the Reporting Period.

¹ 密度的計算方式為本報告期間排放物量除以本集團整體收入。

General waste management

Other than the Three Wastes generated from the manufacturing and productions as mentioned above, general wastes are also generated from the Group's business, mainly consist of paper (for example office paper), as well as domestic wastes from the daily life of the employees. No substantial hazardous general wastes were produced by the Group during the Reporting Period.

The Group has launched a number of general waste management programs, including:

- Encourage the use of emails for internal and external communication, instead of paper fax or physical mailing, so as to reduce paper consumption;
- Use paperless office automation system and human resources information system by encourage the use of electronic system for various internal approval processes and human resource information transmission, such as payment approval, contract approval and employee holiday approval, etc.;
- To encourage staff to reduce paper consumption by double-sided printing and reusing of papers printed on one side; and
- Collect domestic wastes separately and sell the recyclable wastes to the recycling station.

- 將廢棄塑膠、金屬、紙質包裝材料售予廢品回收商作綜合利用。

以下為兩家生產附屬公司於本報告期間產生的固體廢棄物數據：

一般廢棄物管理

除了上述從生產製造過程中產生的三廢外，本集團業務中亦會產生的一般廢棄物，主要包括紙張（例如辦公室用紙）以及員工日常生活產生的生活垃圾。本集團於本報告期間並無產生任何重大有害的一般廢棄物。

本集團推出眾多一般廢棄物管理計劃，包括：

- 鼓勵對內及對外通訊儘量使用電子郵件，取代紙質傳真或郵寄，以減少紙張消耗；
- 使用無紙化辦公自動化系統及人力資源資訊系統，鼓勵各項內部工作審批流程及人力資源資訊傳遞，如付款審批、經濟合同簽訂審批及員工假期報批等，以電子化系統作批覆或信息傳遞；
- 鼓勵員工多採用雙面打印，以及重用已經單面打印的文件；及
- 將生活垃圾分類收集，將可回收垃圾轉賣給回收站再利用。

Production and operation processes are reviewed and analyzed to develop environmental friendly and cost-effective technology so as to reduce emissions, usage of hazardous materials, energy consumption and wastes production. Going forward, the Group targets that the amounts of waste of raw and hazardous materials in 2023 will not be significantly higher than 2022.

2.2 Use of Resources

With the vision of helping to protect the planet and of incorporating environmental sustainability into its business functions and processes, the Group proactively seeks opportunities for increasing operating efficiency in order to reduce the use of resources. The Group also closely monitors the utilisation of resources and reports to senior management on this aspect of performance. Appropriate remedial actions to improve efficiency in the use of resources are taken whenever necessary.

Use of energy

The Group's energy use mainly consists of electricity (including both the production and the domestic use) and diesel and natural gas (the fuel used in the production process).

In addition to the measures mentioned above in the section **"2.1 Emissions – Greenhouse gas and exhaust gas emissions management"** to reduce GHG and exhaust gas emissions to achieve the saving of diesel consumption, in order to further achieve higher energy efficiency, the Group also implemented the following key initiatives to reduce the use of electricity during the Reporting Period:

- Use energy efficient electric appliances as far as possible;
- Maintain the air conditioning temperature of office at about 25°C; and
- Switch off or set to energy saving mode for electric appliances when they are not in use.

本集團檢討和分析生產及操作程序以研發環保和具成本效益的技術，務求減少排放、使用有害物料、消耗能源和產生廢棄物。展望未來，本集團目標為2023年原料浪費及有害材料數額均不會明顯高於2022年。

2.2 資源使用

為助益保護地球及將環境可持續性納入其業務職能及流程，本集團積極尋求提升營運效率的機會以減少資源使用。本集團亦密切監察資源的利用並就此方面的表現向高級管理層匯報。必要時，我們會採取適當的補救措施提升資源使用效率。

能源使用

本集團在能源使用方面主要為電力(含生產及生活用兩者)和柴油及天然氣(生產過程中使用的燃料)。

除上文「**2.1 排放物 – 溫室氣體及廢氣排放管理**」章節中提及的為減少溫室氣體及廢氣排放以達致節約柴油使用的措施外，本集團亦為達致更高能源利用率，於本報告期間，實施以下主要舉措以減少電力使用：

- 盡可能使用能源效益的電器；
- 辦公室空氣調節溫度控制在攝氏25度左右；及
- 關閉不使用的電器，或調校至節能模式。

Energy consumed	能源使用	Unit 單位	Volume Used 用量 Total 總計
Electricity	電力	MWh 兆瓦时	4,604
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	MWh 兆瓦时	11.23
Diesel	柴油	metric ton 公噸	78
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	Megajoules 兆焦耳	0.19
		metric ton 公噸	8,276
Natural gas	天然氣	metric ton 公噸	58
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	0.14
		megajoules兆焦耳	7,266

¹ Intensity is calculated by dividing the volume used by the Group's total revenue during the Reporting Period

¹ 密度的計算方式為本報告期間使用物量除以本集團整體收入

Given the electricity consumption is highly subjected to the business operation and production activities of the Group, fluctuations in electricity usage may be resulted in view to the changes in the Group's business growth and production performance. Going forward, the Group limit the growth of its energy consumption to a level below the corresponding business growth for striving to minimize the accompanied environmental footprints in the future.

鑒於電力消耗受本集團業務經營及生產活動影響較大，本集團業務增長及生產表現的變化可能導致電力消耗出現波動。展望未來，本集團的目標是將其能源消耗數額的增長限制在低於相應業務增長的水平，以努力在未來將伴隨的環境足跡降至最低。

Use of water

The Two Manufacturing Subsidiaries use water supplied by the tap water supply company in China, mainly for the purpose of production and testing of pharmaceuticals, as well as daily life of the employees. The water quality complies with the national drinking water standards of the PRC, and the water supply is sufficient and fully meets our demand. For the effective use of water resources, the Group adopts water conservation management policy, where a variety of effective measures are carried out to reduce water consumption in its scope of operations, such as:

- Formulate "Water Running or Leakage" safety inspection measures to prevent waste of water resource;
- Install loop device for discharged wastewater generated by use of water during the production process, and reuse the cooling water and for greening and watering in the factories, which substantially save water resources and allow reuse to reduce emissions;

用水

兩家生產附屬公司採用中國自來水公司供應水源，主要用於生產及試驗藥品，以及員工日常生活。水質符合中國國家飲用水標準，水源供應充足，完全滿足我們需求。為有效使用水資源，本集團採用節約用水管理政策，在其營運範圍內採取多種有效節約用水措施，比如：

- 制定「跑冒滴漏」安全檢查措施，杜絕浪費水資源；
- 對生產工藝用水產生的排放廢水安裝循環利用裝置，再次利用到冷卻用水循環及廠區綠化澆灌，大大節約水資源及重複利用減少排放；

- Formulate water consumption standards for each production batch and request the production lines strictly follow and execute. The result is regarded as one of the major performance indicator during evaluation;
 - Inspect and maintain water taps and water supply system promptly and periodically to prevent water leakage; and
 - Carefully select production equipment, giving preference to water saving equipment.
- 為各生產品種批次制訂用水量標準，要求車間嚴格遵守及執行，並把執行結果納入主要績效考核；
 - 對水龍頭及供水系統進行及時維修和定期檢查以防漏水；及
 - 謹慎選擇生產設備，優先採用節水設備。

The followings are the data of the water used by the Two Manufacturing Subsidiaries during the Reporting Period:

以下為兩家生產附屬公司於本報告期間用水數據：

Use of resources	資源使用	Unit 單位	Volumed Used 用量 Total 總計
Water	水	metric ton 公噸	78,393
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	191.193

¹ Intensity is calculated by dividing the volume used by the Group's total revenue during the Reporting Period.

¹ 密度的計算方式為本報告期間使用量除以本集團整體收入。

Given the water consumption is highly subjected to the business operation and production activities of the Group, fluctuations in water usage may be resulted in relation to the changes in the Group's business growth and production performance. However, the Group aims to limit the growth of its water consumption to a level below the corresponding business growth for striving to minimize the accompanied environmental footprints in the future.

鑒於用水量受本集團業務經營及生產活動影響較大，用水量可能會因本集團業務增長及生產業績的變化而出現波動。然而，本集團的目標是將其用水量的增長限制在低於相應業務增長的水平，以努力在未來將伴隨的環境足跡降至最低。

Going on, the Group is committed to further develop the awareness in environmental protection among our staffs for maximizing the water efficiency within the Group, and strive to further scale down the corresponding water consumption.

今後，本集團致力進一步提高員工的環保意識，以最大限度地提高本集團的用水效率，並努力進一步降低相應的用水量。

Use of packaging materials

The packaging materials used by the Group mainly include paper, plastic, glass and metal. For the procurement of product packaging materials, the Group has developed a comprehensive procurement management plan and quality control regulations. At the same time, the Group conducts strict on-site audit and quality assessment of raw materials in accordance with regulatory requirements. Only those suppliers that comply with both the relevant national regulations and the Group's quality control regulations are included in our qualified supplier scheme for procurement purpose. The Group also purchases packaging materials based on production plan and demand so as to reduce unnecessary consumption of resources.

包裝物料使用

本集團使用的包裝材料主要包括紙、塑膠、玻璃及金屬。針對產品包裝材料的採購，本集團制定了一套完整的採購管理方案及品質管制規定。同時，本集團對原材料供應商按照法規要求進行嚴格現場審計和品質評估。只有同時符合國家相關規定及本集團品質管制規定的供應商，方會納入合格供應商體系。本集團亦會根據生產計劃按需採購，以減少不必要的資源使用。

According to the requirements of the Good Manufacturing Practice for Pharmaceutical Products, the Group has developed a series of processes and operating procedures for the use of “Raw Materials – Packaging Materials”, including the standard operating procedures (SOP) for collecting and dispatching materials, the process yields as specified in the process regulations, the reasonable waste rate and the balance of materials, where the prescribed consumed and reported material wastes must be inspected on-site, verified and recorded properly, etc.

The followings are the data of the packaging materials used by the Two Manufacturing Subsidiaries during the Reporting Period:

Use of Resources	資源使用	Unit 單位	Volume Used 用量 Total 總計
Packaging materials	包裝物料	metric ton 公噸	1,781
Intensity per HK\$'million revenue ¹	每百萬港元收入密度 ¹	metric ton 公噸	4.344

¹ Intensity is calculated by dividing the volume used by the Group's total revenue during the Reporting Period

¹ 密度的計算方式為本報告期間使用量除以本集團整體收入

根據《藥品生產質量管理規範》要求，本集團制定一系列有關「原材料-包裝物料」使用的工藝規程、操作規程等制度，包括領發料的標準操作規程，工藝規程規定的各工序生產得率、合適損耗率和物料平衡，規定消損耗和報廢物料必須得到現場品質檢驗、確認並有記錄等。

以下為兩家生產附屬公司於本報告期間包裝物料使用數據：

2.3 The Environment and Natural Resources *Air quality*

In order to improve air quality, the Group aims to reduce air emissions generated from its production by green initiatives. The Group is committed to fulfilling and complying with the regime of smoking prevention and control requirements.

2.4 Climate Change *Significant climate-related issues*

Fossil fuel consumptions and human activities are largely responsible for climate change due to increased emissions of heat trapping gases like carbon dioxide into the atmosphere. The Group recognizes the urge to join the endeavour in mitigating the influence of global warming.

With the uncertainties brought by climate change, the Group faces potential physical risks and transition risks. Therefore, integrating climate considerations into the Group's decision-making process is crucial to capital allocation and supply-chain management for developing an effective action plan to adapt its operation to climate change.

2.3 環境及天然資源 *空氣質素*

為幫助改善空氣質素，本集團旨在透過綠色環保措施減少其生產產生的空氣排放量。本集團致力於履行並遵守預防及控制黑煙制度的規定。

2.4 氣候變化 *重大氣候相關事宜*

由於二氧化碳等吸熱氣體排放到大氣中，化石燃料消耗及人類活動對氣候變化負有主要責任。本集團意識到加入減輕全球變暖影響之努力的迫切性。

隨著氣候變化帶來的不確定性，本集團面臨潛在的實體風險及過渡風險。因此，將氣候因素納入集團的決策過程對於資本分配及供應鏈管理至關重要，以製定有效的行動計劃使其運營適應氣候變化。

Physical Risk

The Group is faced with physical risks from the changing climate, which includes a higher frequency and intensity of severe weather events, with extreme precipitation and extreme cyclones being the most dominant threat faced by the Group and its employees. While these events endanger the safety of employees, the production and sales may also be disrupted due to obstructed logistic services or production process caused by the storms. Taking this into account, the Group has formulated the emergency plans for events like typhoon, storm, electricity shortage, network disruption, and breakage of door or window glass etc..

Transition Risk

Policy and legal risk: The pharmaceuticals industry is highly regulated and the regulatory framework, requirements and enforcement trend may be tightened in the future. Although there may be regulatory changes due to climate change in the business operating environment, the Group's business lines are agile and are able to adapt to the policy changes.

Technology Risk: The gradual transition to a low carbon economy has accelerated and increased our investment in technology. The Group has been committed to improving the technology in production, and the Group will consider continuing to invest and develop in the future to reduce environmental pollution caused by production.

Market Risk: The production of the Group has minimal impact in market risk from shifts in the climate change. However, the Group will continue to monitor market-related risks and take actions to reduce market-related risks when necessary.

Reputational risk: During the Reporting Period, the Group has taken measures to transform its business segments and incorporate environmental protection measures into business operations. This aims to align the group's environmental values with potential shifts in public sentiment about climate change.

Nevertheless, the Group is sought to being an environmentally responsible corporation. The Group will continuously optimize its business model and advocate green business, in which the accompanied carbon emissions from its operations can be lowered while ensuring its business development, so that corporate strength could also be enhanced while achieving sustainability concurrently.

實體風險

本集團面臨氣候變化帶來的實體風險，其中包括更頻繁及強度更高的惡劣天氣事件，極端降水和極端氣旋是本集團及其員工面臨的最主要威脅。該等事件危及員工安全，生產及銷售亦可能因風暴造成的物流服務或生產過程受阻而中斷。有鑒於此，本集團已制定若干環境下的應預案，如颱風，暴雨，停電，網絡中斷及玻璃窗門窗破碎等。

轉型風險

政策及法律風險：醫藥行業受到高度監管，監管框架、規定和執法趨勢日後可能會被收緊。儘管業務經營環境可能會因氣候變化而出現監管變化，但本集團業務線靈活，能夠適應政策變化。

技術風險：向低碳經濟的逐步轉型已加速並增加了我們的技術投資。本集團致力於提升生產技術，並將考慮未來繼續為減少生產導致的環境污染而投資開發。

市場風險：氣候變化帶來的市場風險對本集團生產影響微乎其微。然而，本集團將繼續監控市場相關風險，並在必要時採取措施降低市場相關風險。

聲譽風險：於本報告期間，本集團已採取措施轉型其業務分部，並將環保措施納入業務運作，旨在使集團的環境價值觀與公眾對氣候變化情緒的潛在轉變保持一致。

儘管如此，本集團仍致力於成為對環境負責的企業。本集團將不斷優化業務模式，倡導綠色業務，在保證業務發展的同時降低經營中伴隨的碳排放，增強企業實力的同時實現可持續發展。

AWARDS AND RECOGNITIONS

With the joint efforts of the Group, it was awarded the “Caring Company” logo by the Hong Kong Council of Society Services for the third consecutive year during the Reporting Period. The award marked the public’s recognition and the extensive support from society for the Group’s efforts and performance in fulfilling corporate social responsibility and promoting sustainable development for the community.

In terms of business operations and environmental, social and governance (ESG) practices, the performance of the Group was recognized by the industry and won the “Most Valuable Pharmaceutical and Medical Company” Award in the 7th “Zhitong Caijing Listed Company Awards of the Year” and the “ESG Awards” honored by the Television Broadcasts Limited.

The Group will continue to fulfill its corporate social responsibilities by caring for the community and employees, enhancing the health and wellness of the general public as well as promoting the development of traditional Chinese medicine, striving to create long-term social value.

Stakeholders’ Feedback

In addition to reporting our achievements in this ESG Report, we welcome stakeholders’ feedback regarding our ESG approach and performance. Please share your valuable opinions with us through the following ways: -

Correspondence address:	Hong Kong Office, Suites 2405-2410, 24th Floor CITIC Tower No. 1 Tim Mei Avenue Central, Hong Kong
Telephone:	(852) 2545 3313
Facsimile:	(852) 2541 6558
E-mail:	ir@tianda.com

獎項與嘉許

在本集團上下共同努力下，於本報告期間連續第三年獲頒香港社會服務聯會的「商界展關懷」標誌。獎項標示著公眾對本集團在履行企業社會責任、促進社區持續發展的努力和表現備受認可，得到社會廣泛支持。

在業務運營及環境、社會及管治實踐方面，本集團的表現獲得業界認可，分別榮獲第七屆「智通財經上市公司年度評選」中的「最具價值醫藥及醫療公司」大獎，以及電視廣播有限公司頒發的「環境、社會及管治大獎」。

本集團將繼續貫徹履行企業社會責任，關心社會及員工、提升全民健康水平、推動中醫藥發展，致力創造更長遠的社會價值。

持份者的意見回饋

在本環境、社會及管治報告匯報成果之餘，本集團亦歡迎各持份者就本集團的環境、社會及管治方針與表現發表意見。請透過下列方式與本集團分享寶貴意見：-

郵寄地址	香港辦公室 香港中環 添美道1號 中信大廈 24樓2405-2410室
電話：	(852) 2545 3313
傳真：	(852) 2541 6558
電郵：	ir@tianda.com

您的健康是天大的事
TIANDA FOR HEALTH